TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06760065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan Hydrochloride tablets + high dose amoxicillin
Description: Keverprazan Hydrochloride, a potassium-competitive acid blocker (P-CAB), is administered at a dose of 20 mg twice daily in combination with Amoxicillin 0.75 g four times daily for 14 days. This dual therapy is designed to provide rapid and sustained gastric acid suppression and evaluate its efficacy in eradicating Helicobacter pylori.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Susceptibility-Guided Quadruple Therapy
Description: Participants in this arm will receive quadruple therapy tailored to individual H. pylori resistance profiles, including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin, Clarithromycin, Metronidazole, Levofloxacin, or Furazolidone). The regimen is administered for 14 days to optimize eradication outcomes.
Study: NCT06767293

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-InTERACT Parenting Intervention (I2P) and coaching sessions
Description: Online learning sessions for parents of preterm children

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I-InTERACT Parenting Microlearning Intervention (I2P Micro) and coaching sessions
Description: Online microlearning sessions for parents of preterm children

Intervention type: OTHER
Group type: OTHER
Intervention: Internet Resources
Description: control condition
Study: NCT06767358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine hydrochloride
Description: Continuous adjunctive ketamine infusion at a fixed dose of 0.50mg/kg/hour

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Normal saline placebo infusion
Study: NCT06767345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statins, ezetimibe
Description: Rosuvastatin 20mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy
Description: Rosuvastatin 10mg + Ezetimibe 10mg
Study: NCT06768606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER Social-emotional learning curriculum
Description: EMPOWER is a 16-week social-emotional learning curriculum that is integrated into the after-school program context. The STEM Academy program will implement a shortened version of the social-emotional learning curriculum to meet their timelines.
Study: NCT06767683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 4mg
Description: Oral tablet containing 4 mg of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 6mg
Description: Oral tablet containing 6 mg of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 8mg
Description: Oral tablet containing 8 mg of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 10mg
Description: Oral tablet containing 10 mg of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 14mg
Description: Oral tablet containing 14 mg of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680, 18mg
Description: Oral tablet containing 18 mg of ALKS 2680 for once daily administration
Study: NCT06765122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program for Alleviating Relationship Trauma and Stress through New Behaviors (PARTS-NB)
Description: PARTS-NB (Program For Alleviating Relationship Trauma and Stress through New Behaviors) is a group-based program for people who use violence and aggression in intimate relationships. Phase I is 4-weeks of 120 minutes of weekly group-based sessions focused on clarifying the way parts work in the mind, increasing inner compassion and emotion regulation, and explaining the role of trauma and stress in substance use and the use of violence in relationships. Phase II lasts 8-weeks, maintaining the 120 minutes of weekly group-based sessions. This phase introduces the model and focuses on practicing unblending, helping individuals gain awareness and acceptance of internal and external experiences. The final phase, Phase III runs 8 weeks and consists of weekly 120-minute group sessions which addresses and releases trauma-based beliefs and experiences through a process called unburdening.
Study: NCT06769594

Intervention type: DEVICE
Intervention: Investigational Photon-Counting CT Scan
Description: Renal function and pregnancy testing shall be done according to the hospital's SOC. Administration of IV and/or oral contrast material, if applicable, shall be done according to the hospital's SOC. Images will then be compared with the previously acquired imaging conducted as standard of care. The investigational scan takes between 10-30 minutes.~Some imaging protocols require a waiting time of up to 1 hour prior to the scanning session can begin. Cardiac Cohort Subjects will be monitored for 30-60 minutes post-imaging until their blood pressure has returned to pre-imaging level.

Intervention type: DEVICE
Intervention: Investigational Photon-Counting CT Scan
Description: Renal function and pregnancy testing shall be done according to the hospital's SOC. Administration of IV and/or oral contrast material, if applicable, shall be done according to the hospital's SOC. Images will then be compared with the previously acquired imaging conducted as standard of care. The investigational scan takes between 10-30 minutes.~Some imaging protocols require a waiting time of up to 1 hour prior to the scanning session can begin. Cardiac Cohort Subjects will be monitored for 30-60 minutes post-imaging until their blood pressure has returned to pre-imaging level.
Study: NCT06768021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided visualization and standardized pre-sedation instructions
Description: One arm will receive standardized pre-sedation instructions, as well as one-minute guided visualization.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standardized pre-sedation instructions only
Description: One arm will receive standardized pre-sedation instructions only.
Study: NCT06767371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.
Description: Patients with mature permanent molars diagnosed with severe pulpitis with apical periodontitis to be treated with full pulpotomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.
Description: Patients with mature permanent molars diagnosed with moderate pulpitis without apical periodontitis to be treated with full pulpotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Teeth with irreversible pulpitis
Description: Teeth with irreversible pulpitis to be treated with conventional root canal treatment
Study: NCT06769139

Intervention type: OTHER
Intervention: Red blood cell exchange
Description: Red blood cell exchange manual exchange and automatized exchange
Study: NCT06767410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain Intervention
Description: The intervention is distinguished by its multidomain approach combining cognitive, social, and musical activities through choir participation, targeting holistic cognitive and emotional benefits, unlike active controls (general activities) and passive controls (no activities).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General activities
Description: Participants will carry out a series of physical, manual and/or intellectual activities (e.g., horticulture, physical activities, theatre, learning programs etc.) but not musical activities
Study: NCT06767423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text Message + Automated Caller (Intervention)
Description: Standard text message appointment reminders to English and Spanish-speaking patients. Text reminders will go out 3-weeks, 3 days, and 24 hours before the appointment. If patient has not confirmed their appointment after the 3-week and 3-day reminders they will receive an automated caller.
Study: NCT06769087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal
Description: A urinary catheter is removed immediately after surgery and before general anesthesia wears off in the operating room.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: urinary catheter removal within postoperative 1day
Description: The urethral catheter will be removed in the ward within 1 day after surgery (within 24 hours after surgery).
Study: NCT06766253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GMA-TULIP
Description: Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GMA-TULIP
Description: Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GMA-TULIP
Description: Using GMA-TULIP non-inflatable laryngeal mask for airway management in patients who receives laparoscopic surgeries with trendelenburg position.
Study: NCT05242471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered as subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as subcutaneous injection.
Study: NCT05819619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic use of ibuprofen and ondansetron post misoprostol administration
Description: Prophylactic use of ibuprofen and ondansetron post misoprostol administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of ibuprofen and ondansetron at symptom onset post misoprostol administration
Description: Administration of ibuprofen or ondansetron only when experiencing pain or nausea respectively post misoprostol administration.
Study: NCT05622955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Empowered Endometriosis Pain Support (PEEPS)
Description: The sessions will provide education on endometriosis, mindfulness, yoga, nutrition, and strategies to cope with chronic pain. Patients will additionally receive peer and clinician support to decrease the social isolation experienced by people with endometriosis
Study: NCT06525896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NSSD
Description: A robotically-controlled distractive force is applied to the lower back to produce decompression of the spinal column.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NSSD
Description: A robotically-controlled distractive force (lower than the intervention) is applied to tension the belt and create a sense of decompression without producing decompression of the spinal column.
Study: NCT06450444

Intervention type: DEVICE
Group type: OTHER
Intervention: PRIMUS
Description: The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
Study: NCT06045403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Issuing health risk warning for a heat or cold
Description: Whenever a health risk warning for a heat or cold is issued, only the elderly in the combined intervention group will be alerted to the early warning information through the digital heat or cold health risk early warning tool.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A digital heat or cold health risk early warning tool
Description: A WeChat mini-program provides real-time updates on early warnings and health advisories.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perform daily self-monitoring of their BP and ECG
Description: Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perform daily self-monitoring of their BP and ECG
Description: Participants in the self-monitoring alone group were instructed to self-measure their BP three times each morning (from 6:00 a.m. to 8:00 a.m.) and evening (from 6:00 p.m. to 8:00 p.m.) at home, and to self-administer ECG measurements twice during the same morning and evening timeframes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure and ECG device
Description: Devices for self-monitoring blood pressure and electrocardiography (ECG).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-monitoring blood pressure and ECG device
Description: Devices for self-monitoring blood pressure and electrocardiography (ECG).
Study: NCT06277323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly report card intervention
Description: The investigators will increase the frequency (monthly instead of quarterly) and enhance the content of the performance feedback emails sent to cardiologists (i.e., behaviorally-informed).
Study: NCT06450444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMUS
Description: The Salvia PRIMUS System is designed to provide subcutaneous neurostimulation to the branches of the trigeminal and occipital nerves.
Study: NCT05386134

Intervention type: DEVICE
Intervention: Adaptive Optics Retinal Camera
Description: The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.

Intervention type: DEVICE
Intervention: Adaptive Optics Retinal Camera
Description: The rtx1 is a non-invasive device functions without making contact with the eye. The fundus of the patient's eye is illuminated with the IR light emitted from the illumination optical system. The device is comprised of an optoelectronic sensor (OES) that measures the optical defects, software that calculates the necessary corrections and a deformable mirror (DM) that constantly adapts its shape to restore the image's clarity. The digital camera, which is built into the instrument, receives the images and then the images are recorded in the computer hard disk. The AO image software registers and averages the captured image series in order to reduce noise and produce a final enhanced image. The rtx1 integrates AO technology in a flood illumination imaging system and enables visualizing the retina with a high transverse optical resolution of 250 line-pairs per millimeter.
Study: NCT06263231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT230-6
Description: INT230-6 is a fixed combination of cisplatin, vinblastine and SHAO.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Eribulin IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin
Description: Trabectedin infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Pazopanib pill
Study: NCT04554914

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Description: Tabelecleucel is being investigated as an off-the-shelf, allogeneic T-cell immunotherapy for the treatment of EBV+ malignancies and diseases.
Study: NCT05720585

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention of mobile health application
Description: According to the contents of the Subjective Memory Complaint (SMC) application intervention program for the older adults previously formulated, the intervention time and the frequency (30min / time, once a week) of each training module and other contents were determined. The application will be implemented and lasted for a total of 1 month.
Study: NCT06155383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2, Bid orally, D1-14, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2, Bid orally, D1-14, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 130 mg/m2, intravenous infusion, D1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.5 mg/kg, intravenous infusion, D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin
Description: 2.5 mg/kg, intravenous infusion, D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 3.0 mg/kg, intravenous infusion, D1, every 2 weeks
Study: NCT05178121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eLearning Training in Suicide Safety Planning
Description: The training includes a web-based didactic in suicide safety planning, interactive practice in counseling microskills with a chat bot, role-playing safety planning with a standardized patient, and reviewing automated feedback on safety planning counseling skills generated from a computer coding system.
Study: NCT06362759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOUR006 - 50 MG
Description: TOUR006 50 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOUR006 - 25 MG
Description: TOUR006 25 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TOUR006 - 15 MG
Description: TOUR006 15 MG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05164874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Mammography Unit
Description: The main intervention will be a proposition for an appointment at the MMU in complement to the current OBCS
Study: NCT05681039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by IV (vein)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: after care from surgery
Study: NCT05681039

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of life

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given by IV (vein)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given by IV (vein)
Study: NCT06019845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAGiC™
Description: Robotic magnetic radiofrequency (RF) ablation catheter
Study: NCT06277323

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storyboard intervention
Description: The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storyboard intervention
Description: The visibility of the care gap banner in the electronic health record (EHR) upon patient encounter will be enhanced.
Study: NCT06215989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Pill
Description: Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines
Study: NCT06453122

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral care
Description: The intervention group procedure will be carried out in the same way and frequency of the control group, however, replacing the chlorhexidine solution 0.12% for mineral water. Oral hygiene will be carried out by the nursing team, which will be blind to the indices to be evaluated. The team will be previously trained to carry out hygiene procedures by the team of ICU dental surgeons.
Study: NCT06408857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 300 mg SC
Description: MAM01 300 mg will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 300 mg IM
Description: MAM01 300 mg will be administered IM route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 2000 mg IV
Description: MAM01 2000 mg will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 190 mg SC
Description: MAM01 190 mg will be administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAM01 225 mg SC
Description: MAM01 225 mg will be administered SC